AffiliationCancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust Manchester, M20 4BX, UK. Fiona.Blackhall@christie-tr.nwest.nhs.uk
MetadataShow full item record
AbstractGefitinib belongs to the small-molecule class of epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors. It was given conditional approval by the US Food and Drug Administration (FDA) in 2003 for treatment of advanced, chemorefractory non-small-cell lung cancer (NSCLC), but was relabelled for restricted use for patients that were already receiving and benefiting from it after the negative result of the phase III Iressa Survival Evaluation in Advanced Lung Cancer (ISEL) trial. By contrast, erlotinib, another EGFR tyrosine-kinase inhibitor, showed an overall survival benefit compared with placebo and best supportive care in the National Cancer Institute of Canada's BR21 trial, and now has full FDA approval for treatment of patients with NSCLC who have progressed after treatment with chemotherapy. Although the ISEL trial result was negative overall, preplanned subgroup analyses showed a significant overall survival benefit for gefitinib treatment in never-smokers and in patients of Asian origin. Here, we review the clinical experience with gefitinib and, in light of the licensing of erlotinib, address the lessons learned, the ongoing trials, and whether scope remains for clinical development of gefitinib in selected patients.
CitationWhere next for gefitinib in patients with lung cancer? 2006, 7 (6):499-507 Lancet Oncol.
JournalThe Lancet Oncology
- Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.
- Authors: Oxnard GR, Miller VA
- Issue date: 2010 Apr 30
- Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
- Authors: Stinchcombe TE, Socinski MA
- Issue date: 2008 Sep
- Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
- Authors: Patel JD, Pasche B, Argiris A
- Issue date: 2004 Jun
- Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
- Authors: Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ
- Issue date: 2012 Jan
- Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
- Authors: Siegel-Lakhai WS, Beijnen JH, Schellens JH
- Issue date: 2005 Sep